Science behind cisplatin-induced nephrotoxicity in humans: A clinical study

Arunkumar, P A; Viswanatha, Gollapalle Lakshminarayanashastry; Radheshyam, N.; Mukund, H; Belliyappa,

doi:10.1016/s2221-1691(12)60112-9

Cited by 61 publications

(49 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Serum sodium increased by 1.35% in one study, but other electrolytes showed moderately decreased levels. 16 This was attributed to adequate hydration with normal saline during each cycle of chemotherapy. In an Indian Tertiary care hospital based study, 17 hypocalcaemia was the only abnormality.…”

Section: Discussionmentioning

confidence: 99%

Incidence and spectrum of electrolyte disturbances in cisplatin based chemotherapy

Anand¹,

Nikhil²

2015

Int J Res Med Sci

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Incidence and spectrum of electrolyte disturbances in cisplatin based chemotherapy

Anand¹,

Nikhil²

2015

Int J Res Med Sci

View full text Add to dashboard Cite

“…However, this is in contrast to research conducted by Arankumar et al, (2012) in which the value of creatinine serum increased significantly from BUN value after undergoing cisplatin chemotherapy. This might indicate the possibility of severe nephrotoxicity [12]. The contrasting result obtained by this research compared to other literature resources might be triggered by the lack of sufficient samples to provide significant statistics.…”

Section: Creatinine Serum Value Differential Testmentioning

confidence: 58%

“…Besides that, BUN value is also affected by liver because liver is responsible for the conversion of amino acid into urea [3]. [12]. On the other hand, research conducted by Tazcan et al (2013) involving 52 cancer patients that have undergone platinum-based chemotherapy shows a significant increase in BUN value (p<0.05) after going through cisplatin chemotherapy (Tazcan et al, 2013).…”

Section: Bun Value Differential Testmentioning

confidence: 99%

Differences Value of Blood Urea Nitrogen and Creatinine Serum in Cervical Cancer Squamous Cell Stadium Iib-Iiib Before and After Chemotherapy Paclitaxel Cisplatin for Six Cycle in Sanglah General Hospital Denpasar Bali

Noviyani

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: The combination of paclitaxel-cisplatin regimen is one of the chemotherapy regimens used at Sanglah General Hospital, Denpasar. Cisplatin is a potent chemotherapeutic agent, but the nephrotoxic effects of cisplatin reported that research is needed to see the toxic effect on the kidneys before and after 6 series of paclitaxel-cisplatin chemotherapy. Toxicity assessment of the chemotherapy can be observed by evaluating kidney function from monitoring both blood urea nitrogen (BUN) and creatinine serum value. Methods:The research was conducted as an observational study using a prospective cohort method. The research was conducted from January 2016 to June 2016. Patients' follow-up was conducted from the first until the last series of chemotherapy. The data were statistically analyzed with STATA version 14 with paired t-test when the data were normally distributed or the data were analyzed with Wilcoxon test when they were not normally distributed.Results: A total of seven patients were evaluated with both their BUN and creatinine serum values during six series of chemotherapy. Statistically, the BUN and creatinine serum values before the first and after the last paclitaxel-cisplatin chemotherapy series are not statistically significantly different (p>0.05). Conclusion:There are no significant changes of both BUN and creatinine serum values before the first and after the last paclitaxel-cisplatin chemotherapy series in patients with stadium IIB-IIIB squamous cell cervical cancer. Research with larger sample size is essential to provide optimal information for other health-care professionals.

show abstract

“…45.71% patients experienced nephrotoxicity in the PAtreated group, whereas the incidence of nephrotoxicity in NPA-treated group was found to be 13.33%. A statistically significant difference was found in the incidence of nephrotoxicity between PA and NPA-treated group (p=0.0064) [3,12].…”

Section: Discussionmentioning

confidence: 91%

“…Frequency and severity of nephrotoxicity induced by platinum-based chemotherapy may be reduced by slow intravenous electrolyte infusions and maintaining the hydration before, during and immediately after the administration of PAs, especially cisplatin [12].…”

Section: Discussionmentioning

confidence: 99%

Incidence and Management of Treatment-Related Side Effects for Patients Receiving Platinum Therapy in an Outpatient Oncology Clinic

Indhumathi

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Platinum agents (PAs) are the most commonly used chemotherapeutic agents, aiming to induce tumor cell death by cytotoxicity. This leads to have high potential for toxicity and adverse effects. The main objectives of this study were to describe the incidence of side effects caused by platinum therapy and to conclude the management of treatment-related side effects for patients receiving platinum therapy.Methods: A descriptive, retrospective study was carried out over a period of 9 months. Laboratory reports of 100 cancer patients were recorded. All statistical analyses were performed using SPSS 17.0 and GraphPad Prism. A p<0.05 (95% confidence interval) was considered significantly throughout the study.Results: Among 100 patients 55% were male and 45% were female. A total of 70% (n=70) patients who received platinum compounds as chemotherapy regimen, among them 97.14% (n=68) patients appears to have anemia. Among the occurrence of adverse drug reactions, the incidence of anemia was found to be significant (n=68, 97.14%). Statistically significant difference was found in the incidence of anemia between PAs and nonPAs treated group (p=0.0001). Conclusion:Among PAs cisplatin-induced anemia and nephrotoxicity appears to be high in this study. There is a need to improve the management of anemia induced by PAs. Since anemia is preventable, this study emphasizes the need to improve the management of anemia induced by PAs.

show abstract

Science behind cisplatin-induced nephrotoxicity in humans: A clinical study

Abstract: The present study demonstrates that, acute nephrotoxicity was observed in patients with different types of cancers undergoing cisplatin based chemotherapy due to electrolyte disturbances, when no corrective measures were initiated.

Cited by 61 publications

References 6 publications

Incidence and spectrum of electrolyte disturbances in cisplatin based chemotherapy

Incidence and spectrum of electrolyte disturbances in cisplatin based chemotherapy

Differences Value of Blood Urea Nitrogen and Creatinine Serum in Cervical Cancer Squamous Cell Stadium Iib-Iiib Before and After Chemotherapy Paclitaxel Cisplatin for Six Cycle in Sanglah General Hospital Denpasar Bali

Incidence and Management of Treatment-Related Side Effects for Patients Receiving Platinum Therapy in an Outpatient Oncology Clinic

Contact Info

Product

Resources

About